Struggling to find Byooviz? Learn why this biosimilar eye injection is hard to find in 2026 and what you can do to get your treatment on time.
You've been prescribed Byooviz (Ranibizumab-nuna) for your eye condition, and your doctor's office tells you they can't get it in stock. Or maybe your appointment gets pushed back because the clinic is waiting on a shipment. It's frustrating — especially when your vision is on the line.
The truth is, many patients across the country are running into trouble finding Byooviz in 2026. There are real reasons for this, and real steps you can take to get your treatment without dangerous delays.
Byooviz is an FDA-approved biosimilar to Lucentis (Ranibizumab). It's an anti-VEGF injection given directly into the eye to treat serious retinal conditions, including:
Byooviz was the first ophthalmology biosimilar approved in the United States in September 2021, and it became interchangeable with Lucentis in October 2023. That means pharmacies and providers can substitute Byooviz for Lucentis without needing special permission from your prescriber in many states.
It's manufactured by Samsung Bioepis and marketed by Biogen, and it launched at a list price of about $1,130 per vial — roughly 40% less than Lucentis.
For a deeper look at how this medication works, check out our guide on how Byooviz works.
There's no single reason Byooviz can be difficult to track down. Several factors are working together to create availability challenges.
Unlike pills you pick up at the corner pharmacy, Byooviz is a biologic that must be refrigerated and handled carefully. It's distributed through specialty channels — typically shipped directly to retinal specialists' offices or specialty pharmacies. This means your regular pharmacy won't carry it, and availability depends entirely on your eye doctor's supply chain.
Most anti-VEGF injections like Byooviz are handled through a "buy-and-bill" system. Your doctor's office purchases the drug upfront, administers it, and then bills your insurance for reimbursement. If reimbursement rates are too low or unpredictable, some practices may hesitate to stock Byooviz — or may prefer stocking other anti-VEGF treatments like Eylea or Avastin that have more predictable reimbursement.
Even though Byooviz has been available since 2022 and is interchangeable with Lucentis, many retinal specialists have been slow to switch. Some providers prefer medications they've used for years, and the overall anti-VEGF market has shifted toward newer drugs like Vabysmo (Faricimab) and Eylea HD (high-dose Aflibercept). If your doctor hasn't added Byooviz to their formulary, they may not have it on hand.
Some insurance plans — especially Medicare Advantage plans — require prior authorization before covering Byooviz. Others may require step therapy, meaning you have to try a cheaper option like compounded Avastin (Bevacizumab) first. These delays can create gaps in treatment and make it seem like the drug is "unavailable" when it's really an insurance issue.
Even when availability is tight, there are concrete steps you can take to get your Byooviz injection on schedule.
The fastest way to check which providers or pharmacies near you have Byooviz in stock is to use Medfinder. It's a free tool that helps patients locate medications — including hard-to-find specialty drugs — in real time.
Not all eye doctors stock the same medications. If your current provider can't get Byooviz, another retinal specialist in your area might have it readily available. Our guide on finding a doctor who prescribes Byooviz can help you search.
Biogen offers a dedicated support line at 1-877-422-8360 that can help locate Byooviz and connect you with providers who carry it. They can also help with insurance issues and copay assistance.
If your injection is due and Byooviz isn't available, ask your doctor about temporarily using an alternative anti-VEGF treatment to avoid a gap in care. Learn more about your options in our article on alternatives to Byooviz.
Call your doctor's office a week before your scheduled injection to confirm they have Byooviz in stock. This gives them time to order it if needed, and gives you time to find another provider if there's a problem.
Byooviz is an effective and more affordable alternative to Lucentis for treating serious eye conditions, but finding it in 2026 can take some extra effort. The specialty supply chain, insurance hurdles, and slow biosimilar adoption all play a role.
The most important thing is to not skip or delay your injections. Vision loss from wet AMD, RVO, and mCNV can be permanent. If you can't find Byooviz, talk to your doctor about a backup plan — and use tools like Medfinder to stay ahead of the problem.
For more information, read our Byooviz shortage update for 2026 or learn about how to save money on Byooviz.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
